J. Nichols

Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

P. Wallace, F. Hernandez-Ilizaliturri, S. Sait, 2022, Cancer.

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

F. Hernandez-Ilizaliturri, C. Mavis, P. Torka, 2022, Blood advances.